Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 12;42(8):1315-1318.
doi: 10.1016/j.ccell.2024.06.015. Epub 2024 Jul 18.

Tumor-infiltrating lymphocytes: A new hope

Amod A Sarnaik  1 , Patrick Hwu  2 , James J Mulé  2 , Shari Pilon-Thomas  3
Affiliations
Free article
Review

Tumor-infiltrating lymphocytes: A new hope

Amod A Sarnaik et al. Cancer Cell. .
Free article

Abstract

Tumor-infiltrating lymphocytes (TILs) can be massively expanded from resected tumors and used as a cellular treatment for advanced malignancies. TILs require a preparative non-myeloablative chemotherapy followed by an abbreviated course of interleukin-2. Here, we review the historical development of TIL therapy and discuss potential solutions to ongoing roadblocks that may result in broader and improved efficacy for patients afflicted with treatment-refractory, advanced cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.A.S. is a co-inventor on patient applications involving adoptive cell therapy for cancer that has been licensed to Iovance Biotherapeutics and is a co-inventor on a patent application with Provectus Biopharmaceuticals; reports research funding from Iovance Biotherapeutics and Turnstone Biologics; and reports personal fees from Guidepoint, Gerson Lehrman Group, Second City, Blueprint Oncology Concepts, Boxer Capital, and Istari Onc. P.H. serves on the scientific advisory boards of Immatics, Dragonfly Therapeutics, and Adventris Pharmaceuticals. J.J.M. has ownership interest in Aleta Biotherapeutics, CG Oncology, Turnstone Biologics, Ankyra Therapeutics, and AffyImmune Therapeutics and serves on the scientific advisory boards of CG Oncology, Turnstone Biologics, Vault Pharma, Ankyra Therapeutics, AffyImmune Therapeutics, UbiVac, Vycellix, and Aleta Biotherapeutics. S.P. is a co-inventor on patent applications involving adoptive cell therapy for cancer that has been licensed to Iovance Biotherapeutics and Tuhura Biopharma; is a co-inventor on a patent application with Provectus Biopharmaceuticals; reports research funding from Iovance Biotherapeutics, Provectus Biopharmaceuticals, Intellia Therapeutics, Dyve Biosciences, Turnstone Biologics, and Cellgene; and reports personal fees from Seagen, Morphogenesis, and KSQ Therapeutics.

LinkOut - more resources